The laboratory criteria of the antiphospholipid syndrome include one coagulation assay (lupus anticoagulant [LA]) and two solid phase assays (anticardiolipin [aCL] and anti-ß 2 glycoprotein I antibodies [aß 2 GPI]). External quality control (EQC) surveys show that negative and clearly positive LA samples are classified correctly by about 95% of laboratories. For 'weak' LA there is a wide variability in samples' classification. Furthermore, when a weak LA sample is used in two different EQC surveys more than 50% of laboratories classify it differently. In some surveys weak LA samples were found to be positive for aCL and for aß 2 GPI by a majority of laboratories; the main reason for laboratories which classified these samples as LA negative was a negative result in the mixing test. It is likely that, depending on the sensitivity of the assay, a weak LA cannot be detected anymore after 1:1 dilution of the sample with normal plasma. Therefore, we recommend the use of integrated assays, such as screen/ confirm ratios, for the detection of weak LA samples. Lupus (2012) 21, 722-724.
Introduction
The antiphospholipid syndrome (APS) was described in the early 1980s. This syndrome consists of the association of clinical events (thrombosis and/or obstetrical morbidity) and the presence of antiphospholipid antibodies (aPL). A consensus conference held in Sapporo in 1998 defined the clinical and laboratory (lupus anticoagulant and anticardiolipin antibodies IgG/IgM) criteria of the syndrome. 1 The need for a better standardization of the assays was also stressed at this meeting. In 2004 these criteria were revised in Sydney and the presence of aß 2 GPI (IgG and IgM) was added as a new laboratory criterion. 2 Despite of the many efforts for standardization, the variability between laboratories and assay systems was found very high in the comparative studies as well as in external quality control surveys.
Lupus anticoagulant testing
Lupus anticoagulant (LA) prolongs the clotting time of assays which depend on the presence of phospholipids (PL). The sub-committee on standardization on LA and aPL of the ISTH published guidelines for LA testing in 1995. 3 Briefly, a threestep procedure was designed comprising: (i) a screening test depending on the presence of PL; (ii) if prolonged, the screening test is performed again on a mixture sample:normal human plasma (to rule out factor(s) deficiency); (iii) if the mixture fails to correct the clotting time, a confirmatory test using the same assay as the screening test but after addition of PL is performed (to ascertain PL dependency). In 2009 these guidelines were updated. 4 Briefly, the experts recommended the dilute Russell's viper venom time (dRVVT) and a LA-sensitive activated partial thromboplastin time (aPTT), the proportions (1:1) and the absence of incubation of the mixture sample:normal human plasma and the way to calculate the percentage of correction of the clotting times. In addition, they included the so-called integrated assays, where the mixing tests may be omitted.
External quality control surveys showed that laboratories obtain good results (about 95% of correct results), when the samples to be analysed were negative or clearly positive. In contrast, there was a wide variability in sample classification when the sample was a 'weak' positive (Table 1) . Since LA cannot be quantified, a 'weak' LA is believed to prolong moderately the clotting times. In this respect, the same sample sent in two surveys was reported with different classifications. Some laboratories classified this sample as positive in the first survey and negative in the second one, and vice versa ( Table 2 ) which emphasizes the difficulty faced by many laboratories to classify a 'weak' LA.
Because our knowledge of the natural history of LA is very limited it is impossible to neglect these 'weak' LA. The use of integrated tests (for example, the ratio of screen reagent clotting time/confirm reagent clotting time and the ratio of LA-sensitive aPTT reagent clotting time/LA-insensitive aPTT reagent clotting time) without mixing test, may be helpful in these cases to avoid diluting the samples 1:1 in normal human plasma that may mask the 'weak' LA. The absence of factor(s) deficiency may be checked by prothrombin time (for dRVVT) and a factor deficiency-sensitive LA-insensitive aPTT reagent. The percentage correction in clotting time obtained with the confirm reagent and the aPTT insensitive reagent must be computed in order to rule out the presence of an inhibitor directed to a coagulation factor.
The negative results for 'weak' LA presented in Table 1 were further analysed in order to determine which test (screening, mixing or confirmation) of the three-step procedure led to the final LAnegative classification ( Table 3 ). In addition the percentage of positive IgG aCL and IgG aß 2 GPI was computed. In five out of eight surveys a majority of laboratories had positive results for both solid phase assays. In all except one survey (2008-3), the main cause of a negative LA classification arose from the mixing test. Because aCL and aß 2 GPI were found positive by the majority of laboratories it is likely that a weak LA was present. It has been reported that there is a correlation between the number of positive tests and the clinical course of the disease. 5 These data supports the fact that integrated procedures should be adopted when looking for weak LA in order to avoid falsenegative results. The occurrence of false-negative results has been already reported 6 and in particular related to mixing tests. 7, 8 Therefore, a negative mixing test, especially for a weak lupus positive sample, does not automatically mean a negative lupus sample.
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